TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03698578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combat fight
Description: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combat fight
Description: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
Study: NCT01762774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
Study: NCT01078285

Intervention type: BEHAVIORAL
Intervention: Adherence Counseling
Description: Patients receive 3-5 minutes of adherence counseling, and other patient support services
Study: NCT02422615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib capsules were administered orally at a daily dose of 600mg for 21 consecutive days within a 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.
Study: NCT04717115

Intervention type: GENETIC
Intervention: Genetic diagnosis
Description: No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed
Study: NCT02695498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class \[9 total classes.\] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine/stress Education
Description: The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
Study: NCT04578431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artificial sweeteners (acesulfame-potassium, sucralose, saccharine, cyclamate)
Description: The intervention is found in light products ingested by millions of people on a daily basis worldwide
Study: NCT00495183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: Biperiden 2-4 mg/d, divided in 2 doses per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04686071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF method
Description: Treatment in the study group was conducted with PNF method with a use of indirect training based on irradiation phenomenon. The program included: proprioceptive stimulation of the operated limb, improving trunk stabilization and active control, active foot training, muscle strength facilitation of lower limbs in closed kinematic chain with considering periarticular stabilization within the operated knee joint as well as exercises improving mobility of the operated knee, verticalization and locomotion with emphasis on the stance phase.
Study: NCT01762774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
Study: NCT02422615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant was administered via intramuscular injections at a dose of 500mg every 28 days, starting on Day 1 of each cycle. In Cycle 1, an additional dose of Fulvestrant was given on Day 15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules were administered orally for 21 consecutive days within a 28-day cycle.
Study: NCT00990808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: \[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: \[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: atorvastatin
Description: Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to MK0859
Description: Placebo to MK0859 once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to MK0859
Description: Placebo to MK0859 once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo to atorvastatin
Description: Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
Study: NCT03839823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole OR Anastrozole
Description: Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Dose: 3.6 mg Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.~Subcutaneous implant
Study: NCT03275714

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone APP
Description: Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone APP
Description: Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
Study: NCT04386486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bathe anamnesis method
Description: BATHE anamnesis (BA) is applied to first group and preoperative examinations are completed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standart anamnesis
Description: standart anamnesis is applied to second group and preoperative examinations are completed.
Study: NCT03605225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mobile cellphone application test
Description: Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
Study: NCT03050307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 Placebo
Description: TAK-438 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Lansoprazole placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-Containing Quadruple Therapy
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth-Containing Quadruple Therapy
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Study: NCT02812615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg
Description: After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole/Pyrantel Pamoate
Description: As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Parents/caregivers will be given nutritional counselling

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrient sprinkles
Description: For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
Study: NCT04476615

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-Mimicking Diet (ProLon®)
Description: Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo bars
Description: Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day.~5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).
Study: NCT02209259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Upper Extremity Function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Upper Extremity Function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS Upper Extremity Function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain intensity
Study: NCT01036724

Intervention type: DEVICE
Intervention: Cardiac Mapping
Description: Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.

Intervention type: DEVICE
Intervention: Cardiac Mapping
Description: Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX\[TM\]) and measuring the amount of radiation exposure duration for each.
Study: NCT02034292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT01222117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection
Study: NCT02034292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study: NCT02209259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive affect negative affect scale (PANAS)
Study: NCT01222117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmin
Description: Plasmin prepared in 0.9% saline for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasminogen Activator
Description: Plasminogen activator used according to the Investigator's clinical judgment.
Study: NCT04686071

Intervention type: OTHER
Group type: OTHER
Intervention: Standard rehabilitation
Description: In the control group standard rehabilitation protocol was used in patients following TKA, which is mainly based on activities in open chains (passive exercises with continuous passive motion (CMP) device, active exercises, isometric, active resistance, patella mobilization, deep tissue massage, verticalization and gait relearning).
Study: NCT02590081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Study: NCT04873804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Study: NCT01222117

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for injection at the same volume as the plasminogen activator.
Study: NCT02209259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive affect negative affect scale (PANAS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive affect negative affect scale (PANAS)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard PCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positively-adjusted version of the PCS
Study: NCT01964027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second line chemoregime for advanced gastric cancer
Description: Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment \* 6 cycles as the second line chemoregime for advanced gastric cancer
Study: NCT02055729

Intervention type: BIOLOGICAL
Intervention: 3mm tissue punch biopsy
Description: Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).

Intervention type: BIOLOGICAL
Intervention: Superficial bedsore sample
Description: Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 \& 28)

Intervention type: BIOLOGICAL
Intervention: Stool sample
Description: Stool samples will be collected on days 0 and 28.

Intervention type: BIOLOGICAL
Intervention: Urine sample
Description: Urine samples will be collected on days 0 and 28.
Study: NCT03613168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab plus gemcitabine/cisplatin
Study: NCT02145754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MKP media
Description: one half of skin specimen was put in MKP media

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSK-H media
Description: one half of skin specimen was put in BSK-H media
Study: NCT03185091

Intervention type: OTHER
Group type: OTHER
Intervention: rapid ventricular pacing

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Study: NCT01200563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure
Description: Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy and Negative Pressure Wound Therapy
Description: MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
Study: NCT04287205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone
Description: 79 women, aged between 18 and 45 years, who were examined at our tertiary gynecology outpatient clinic between April 2019 and March 2020, with surgically diagnosed endometriosis, were included in this study. They received a treatment with 5 mg dydrogesterone administered orally twice daily for 21 days; from the 5th to 25th day of each menstrual cycle, for a total of 6 months. They were evaluated pre- and posttreatment in terms of their age, parity, and body mass index (BMI). Female Function Sexual Index (FSFI) and visual analogue scale (VAS) scores were recorded pre- and posttreatment
Study: NCT04873804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intervention protocols were applied using tDCS (Teknofil TESsaNova). All individuals received 2 mA of anodal tDCS for 2 weeks on weekdays. All applications were done in the form of 20-minute sessions.
Study: NCT01575236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian Laryngeal Mask
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway
Description: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
Study: NCT02634775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in treatment strategy
Description: Start on dialysis, transplantation, change of PD prescription, change of HD prescription

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in treatment strategy
Description: Start on dialysis, transplantation, change of PD prescription, change of HD prescription

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in treatment strategy
Description: Start on dialysis, transplantation, change of PD prescription, change of HD prescription
Study: NCT02974140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract Refractive Suite (CRS)
Description: Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Refractive Suite (CRS)
Description: Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard manual technique
Description: Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard manual technique
Description: Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
Study: NCT00814580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Description: First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR
Description: First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed